EZR and cervical cancer: For the TNM and FIGO clinical stages, the strongly positive rate of ezrin protein was 96.1% (122/127) in advanced (stages IIB–IV) cervical cancers, but only 49.1% (53/108) in early stage cases (I–IIA) (P<0.05).